- First three times weekly glatiramer 40 mg/mL
- Approval obtained, in close collaboration with partner Synthon
- Provides an affordable, high-quality alternative to MS patients, complemented by a range of support services including AutoxonTM
Alvogen today announced the successful closure of the decentralized procedure for RemurelTM (glatiramer acetate) 40 mg/mL, the first generic equivalent of CopaxoneTM 40 mg/mL in Europe.
Alvogen is already successfully marketing a once daily subcutaneous 20 mg/mL prefilled syringe under the brand name RemurelTM. The approval of the generic three times weekly 40 mg/mL is excellent news for the multiple sclerosis community, providing a high-quality and affordable alternative.
Teva‘s CopaxoneTM delivered sales of over EUR 505 million in Europe in 2016, according to IMS Midas data.